Author:
Stroda Alexandra,Thelen Simon,M’Pembele René,Tenge Theresa,Jaekel Carina,Schiffner Erik,Bieler Dan,Bernhard Michael,Huhn Ragnar,Lurati Buse Giovanna,Roth Sebastian
Abstract
AbstractHemodynamic stabilization plays a crucial role in the treatment of patients suffering from severe trauma. Current guidelines recommend the early administration of tranexamic acid (TXA) for bleeding control. While less blood loss can result in less end-organ damage, including myocardial injury, TXA also exhibits prothrombotic effects with potentially adverse myocardial effects. The aim of this study was to investigate the association between the administration of TXA and myocardial injury in patients with severe trauma. We conducted a monocentric cohort study including severely injured patients ≥ 18 years [defined by Injury severity score (ISS) ≥ 16], who were admitted to a tertiary care hospital between 2016 and 2019. Primary outcome measure was myocardial injury according to the fourth Universal Definition (= high sensitive troponin T ≥ 14 ng/l). Secondary endpoints were in-hospital major adverse cardiovascular events (MACE) and mortality. Main exposure was defined as administration of TXA during prehospital period. We conducted multivariate logistic regression models including predefined covariables. A total of 368 patients were screened. Among the 297 included patients (72% male, age. 55?21 years), 119 (40%) presented myocardial injury at hospital arrival. TXA was administered to 20/297 (7%) patients in the prehospital setting, and in 96/297 (32%) patients during pre-or in-hospital period. MACE incidence was 9% (26/297) and in-hospital mortality was 26% (76/297). The adjusted odds ratios (OR) for prehospital TXA and myocardial injury, MACE and mortality were 0.75 [95% confidence interval (CI): 0.25–2.23], 0.51 [95%CI: 0.06–4.30] and 0.84 [0.21–3.33], respectively. In the present cohort of patients suffering from severe trauma, prehospital TXA did not affect the incidence of myocardial injury.
Funder
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Hematology
Reference16 articles.
1. DGfrU eV (2022) S3-Leitlinie Polytrauma/Schwerverletzten-Behandlung (AWMF Registernummer 187 – 023), Version 4.0 https://www.awmf.org/leitlinien/detail/ll/187-023.html2023 [28.06.2023]. Available from: https://register.awmf.org/assets/guidelines/187-023l_S3_Polytrauma-Schwerverletzten-Behandlung_2023-06.pdf
2. Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L et al (2013) The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess 17(10):1–79 PubMed PMID: 23477634; PubMed Central PMCID: PMCPMC4780956
3. Ng W, Jerath A, Wasowicz M (2015) Tranexamic acid: a clinical review. Anaesthesiol Intensive Ther 47(4):339–350 Epub 20150323. doi: 10.5603/AIT.a2015.0011. PubMed PMID: 25797505
4. Collaborators WT (2017) Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 389(10084):2105–2116 Epub 20170426. https://doi.org/10.1016/S0140-6736(17)30638-4
5. Devereaux PJ, Marcucci M, Painter TW, Conen D, Lomivorotov V, Sessler DI et al (2022) Tranexamic acid in patients undergoing noncardiac surgery. N Engl J Med 386(21):1986–1997 Epub 20220402. doi: 10.1056/NEJMoa2201171. PubMed PMID: 35363452